my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
09-08-2012: Evonik Industries AG and BRAIN AG co-operate in the field of the development of novel
microorganisms with unique, selective binding- and adsorption characteristics on selected surfaces.
Within the co-operation the partners pursue the joint objective of identifying and developing suitable microorganisms, which, by using their adsorption properties, will specifically introduce novel physical properties to the selected surfaces.
It is the goal of the partners to integrate the selected microorganisms into an industrial-scale. BRAIN will contribute its expertise in biotechnology, microbiology and the development of pilot processes, while Evonik shall be responsible for the technical implementation and marketing of the products. Financial terms of the collaboration or more detailed technical information are not disclosed.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Evonik selects OPX Biotechnologies for joint development of bio-based chemicals
OPX Biotechnologies, Inc. (OPXBIO) and Evonik Industries AG announced the two companies have entered into an agreement to jointly develop certain bio-based specialty chemicals. The joint-development agreement signed May 3rd 2013 calls for OPXBIO to use its proprietary EDGE™ (Efficiency Dir ... more
Evonik invests heavily in biotech
Evonik Industries plans to continue expanding its commitment to biotechnology. “Biotech opens up interesting opportunities for profitable growth in a range of business areas,” says Patrik Wohlhauser, a member of the Executive Board. “It’s also giving Evonik’s growth strategy a stronger focu ... more
Evonik Industries and BRAIN co-operate
Evonik Industries AG and BRAIN AG co-operate in the field of the development of novelmicroorganisms with unique, selective binding- and adsorption characteristics on selected surfaces. Within the co-operation the partners pursue the joint objective of identifying and developing suitable mic ... more
BRAIN-led industrial NatLifE 2020 innovation alliance started after receipt of approval
As the industrial coordinator of the innovation alliance, the biotechnology company BRAIN AG has announced that the Natural Life Excellence Network 2020 (NatLifE 2020) innovation alliance is the first alliance to receive the official approval letter under the “Industrial Biotechnology Innov ... more
BRAIN expands its IP Portfolio with bioactive Compound MMPI
BRAIN AG has announced the expansion of its IP portfolio to include the MMPI (matrix metalloproteinase inhibitor) peptide. Now owned by BRAIN, the recombinant human bioactive molecule will be manufactured by BRAIN as a proprietary bioactive compound going forward and exclusively used in cos ... more
BRAIN announces €60m round of financing to expand its buy-and-build strategy
The supervisory board and the board of management of the biotechnology company BRAIN AG agreed on a €60m capital increase during a meeting of the supervisory board held on 19 November 2012. The capital increase helps pave the way for the implementation of BRAIN’s “buy-and-build” industriali ... more
BRAIN Biotechnology Research And Information Network AG
BRAIN AG is an industrial “white” biotech company which discovers and develops novel bioactive natural compounds and proprietary enzymes for its partners and customers in the chemical and pharmaceutical industries, as well as the food and cosmetics industries. With its unique approach to th ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
